Boston Children’s nurses: Setting the standard for innovation

As clinicians at Boston Children’s Hospital continue to pioneer new therapies for both kids and adults, nurses play a critical role in bringing those treatments to families. To make sure groundbreaking treatments like gene therapies are integrated into both nursing practice and patient care, Boston Children’s nurses have developed a series of processes.
When a new drug or treatment becomes available, our nurses lead by pulling all the intersecting pieces together to ensure the process flows and quality and safety remain at the forefront. This includes the design and delivery of:
- tailored clinical education programs
- patient and family education materials
- orders and standards of practice
- pathways and workflows
- new equipment
- physical space
Collaboration in action
The use of a gene therapy called tisagenlecleucel (brand name KYMRIAH) serves as a powerful example of this work. In 2018, Dana Farber/Boston Children’s Cancer and Blood Disorders Center became one of the first sites in the country certified to administer this drug to patients with acute lymphoblastic lymphoma. Nurses were at the table with physicians, scientists, pharmacists, and others to coordinate deployment of the therapy to our patients. Together, research and stem cell transplant nurses developed an intensive education program that helps frontline nurses perform multiple steps in the KYMRIAH process, including the collection of T cells, chemotherapy conditioning, infusion, and recovery.
As the development of life-changing therapies accelerates, Boston Children’s nurses are ready, says Colleen Dansereau, MSN, RN, CPN, director of clinical operations for the hospital’s Gene Therapy Program, and director of clinical research nursing at Dana Farber/Boston Children’s Cancer and Blood Disorders Center. “Our clinicians have learned to think in new, creative ways to shift the model of how medicine is practiced,” she says. “We’re ahead of the game because we already have an innovative program in place.”
Related Posts :
-
Sickle cell gene therapy and boosting fetal hemoglobin: A 75-year history
Ed. Note: This post updates an earlier post from 2018. In a landmark decision today, the Food and Drug Administration (FDA) ...
-
Here’s how genetic vision testing can help your family
At least 600 of the roughly 20,000 genes in the human body are needed for normal eyesight. Changes in those genes can ...
-
Making immunotherapy safe for AML
Acute myeloid leukemia (AML), the second most common leukemia in children, is hard to treat and has a five-year survival ...
-
Conquering a rare metabolic condition: A family, a pediatrician, and two labs join forces
As a newborn, Sam Hoffman never cried or made a sound. His mother, Carolyn, often had to wake him up ...